Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir
- 5 December 2021
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 23 (4) , 362-370
Abstract
Objectives: Tenofovir disoproxil fumarate (TDF) is associated with reduced bone mineral density (BMD). The aim of the study was to evaluate changes in BMD in women who switched from TDF, emtricitabine and a nonnucleoside reverse transcriptase inhibitor (TDF/FTC/NNRTI) to abacavir, lamivudine and dolutegravir (ABC/3TC/DTG).Methods: We conducted a randomized controlled trial in which women aged ≥ 40 years were randomized 1:2 to continue TDF/FTC/NNRTI or switch to ABC/3TC/DTG. We analysed changes in BMD at the hip and lumbar spine from baseline to week 96 using linear regression, and markers of bone turnover and kidney function using repeated measures mixed effects models with multiple imputation for missing data. We conducted exploratory analyses of weight, mental health, sleep and symptoms attributed to HIV infection and antiretroviral therapy.Results: Ninety‐one women [mean (standard deviation) age 50.4 (6.6) years] were randomized. Women who switched to ABC/3TC/DTG maintained viral suppression and experienced improvements in BMD at the lumbar spine (but not the neck of the femur or the total hip), bone resorption markers and proteinuria (total protein, albumin and retinol‐binding protein) and modest weight gain without changes in body mass index. Although mean anxiety, depression and sleep scores did not differ between the two study arms, anxiety, depression and sleep disturbance at baseline predicted ABC/3TC/DTG discontinuation for neuropsychiatric side effects [odds ratios (95% confidence intervals) 11.9 (2.0–71.6), 16.0 (2.6–97.9) and 10.0 (1.8–56.0), respectively].Conclusions: Switching from TDF/FTC/NNRTI to ABC/3TC/DTG improved the BMD of the lumbar spine and kidney function. These benefits need to be balanced against modest weight gain and the need for antiretroviral therapy substitutions in a proportion of participants.Keywords
Funding Information
- ViiV Healthcare
This publication has 41 references indexed in Scilit:
- Future challenges for clinical care of an ageing population infected with HIV: a modelling studyThe Lancet Infectious Diseases, 2015
- Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed SuicideAnnals of Internal Medicine, 2014
- Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapyAIDS, 2014
- Antiretrovirals and the kidney in current clinical practiceAIDS, 2014
- Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate ExposureThe Journal of Infectious Diseases, 2014
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Association of tenofovir exposure with kidney disease risk in HIV infectionAIDS, 2012
- Semiparametric predictive mean matchingAStA Advances in Statistical Analysis, 2008
- A scale for the estimation of sleep problems in clinical researchJournal of Clinical Epidemiology, 1988
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983